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Figure S1. Southern blot analysis of integrity of the alphoidtetO-HAC-GFP in hamster CHO 
cells (clone 38-18) and after MMCT into hiPSCs (clone R1). Genomic DNA possessing the 
HAC isolated from CHO and hiPSCs was digested with SpeI endonuclease which cuts the 
HAC only in the vector part, and separated by CHEF gel electrophoresis (range 10−300 kb). 
The transferred membrane was hybridized with the tetO-alphoid probe (see Materials and 
Methods). M - Markers: CHEF DNA Size Lambda Ladder (BIO-RAD) and 8-48 kb DNA size 
standards (BIO-RAD)  
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Figure S2. hiPSCs bearing the alphoidtetO-HAC-GFP express pluripotency markers. 
alphoidtetO-HAC-GFP hiPSCs (clone R1) maintained for over 5 passages in ES cell 
culture conditions remain pluripotent as they express OCT4, and SOX2 markers (red), 
indicated on the panels. Scale bar, 400 mm. 
GFP+	 GFP-	
1st	passage	
a-HAC-GFP a-HAC-GFP 
GFP+ 
a	
b	
c	
2nd	passage	
d	
GFP+ 
Figure S3. Silencing of GFP expression in a fraction of alphoidtetO-HAC-GFP hiPSCs. (a) FACS of 
alphoidtetO-HAC-GFP hiPSCs (R2.3) after 5 passages, images of GFP+ and GFP– cell fractions 
seeded on Matrigel-coated wells after cell sorting. (b) Images of the above GFP+ and GFP– on day 7 
after seeding, (c, d) rare cells show onset of GFP expression in GFP– cell fractions already after 1-2 
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Figure S4. FISH analysis of FACSed alphoidtetO-HAC-GFP hiPSCs revealed loss of the HAC in the 
population of GFP-negative cells. GFP-positive and GFP-negative cells were separated by FACS, and 
cultured for 7 days before the FISH assay. Summary of metaphase spread counts represented on the 
Table S1. Examples of metaphase nuclei from populations of GFP-positive and GFP-negative cells 
shown at passage 5 following the FACS. AlphoidTetO HAC-GFP is revealed with tetO PNA-FITC as a 
probe. The HACs (green, arrows) colocalizes with DAPI (blue) but not with PNA-TRITS labeled 
telomere probe (red), which is specific exclusively for host chromosomes.  
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Figure S5. AZA and TSA treatment of alphoidtetO-HAC-GFP hiPSCs does not increase 
number of GFP-positive cells. (a) 24-hour treatment of the cells with indicated high 
concentrations of AZA (5, 10 uM) and TSA (0,5 uM) does not increase number of GFP 
positive cells, however, it further increases GFP expression in already GFP-positive cells. 
(b) 24-hour cultivation of alphoidtetO-HAC-GFP hiPSC with low concentrations of AZA 
(100, 400 nM) and TSA (19, 38 nM) does not affect number of GFP-positive cells. GFP-
negative cells indicated by arrows. Control untreated cells and treated with ethanol 
vehicle (Eth) are indicated.  (c) Prolonged cultivation (72 hrs) of alphoidtetO-HAC-GFP 
hiPSCs with 400 nM AZA does not affect number of GFP-positive cells if compare with 
control.  
